Suchergebnisse - "Huang, Chaolin"

PubPharm (104)

1

Multi-cohort study on cytokine and chemokine profiles in the progression of COVID-19

enthalten in: Scientific reports | 2024

von Huang, C. | Hu, X. | Wang, D. | +11

2

Broad phenotypic alterations and potential dysfunctions of lymphocytes in COVID-19 recovered individuals

enthalten in: bioRxiv.org | 2024

von Yang, J. | Zhong, M. | Zhang, E. | +14

3

FGF7 enhances the expression of ACE2 in human islet organoids aggravating SARS-CoV-2 infection

enthalten in: Signal transduction and targeted therapy | 2024

von Meng, H. | Liao, Z. | Ji, Y. | +15

4

Human monoclonal antibody F61 nasal spray effectively protected high-risk populations from SARS-CoV-2 variants during the COVID-19 pandemic from late 2022 to early 2023 in China

enthalten in: Emerging microbes & infections | 2024

von Liu, Y. | Zhang, J. | Liu, W. | +20

5

Effect of Corticosteroids on Long-term Humoral and Memory T-Cell Responses in Follow-up Visit of Hospitalized Patients With COVID-19

enthalten in: Chest | 2024

von Wang, Y. | Guo, L. | Fan, G. | +19

6

Corrigendum : Associations between omega-3 fatty acids and insulin resistance and body composition in women with polycystic ovary syndrome

enthalten in: Frontiers in nutrition | 2024

von Lu, L. | Li, X. | Lv, L. | +3

ErratumFor: Front Nutr. 2022 Oct 05;9:1016943. - PMID 36276838

7

Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China : a multicentre, double-blind, phase 3, randomised controlled study

enthalten in: The Lancet. Infectious diseases | 2024

von Fan, X. | Dai, X. | Ling, Y. | +36

8

Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir : a multicentre randomised, double-blind, placebo-controlled phase 3 trial

enthalten in: EClinicalMedicine | 2024

von Zhan, Y. | Lin, Z. | Liang, J. | +37

9

Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19

enthalten in: The New England journal of medicine | 2024

von Cao, B. | Wang, Y. | Lu, H. | +28

CommentIn: N Engl J Med. 2024 Apr 25;390(16):1533-1534. - PMID 38657253

10

3-year outcomes of discharged survivors of COVID-19 following the SARS-CoV-2 omicron (B.1.1.529) wave in 2022 in China : a longitudinal cohort study

enthalten in: The Lancet. Respiratory medicine | 2024

von Zhang, H. | Huang, C. | Gu, X. | +9

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[11]